Taro Pharmaceuticals Inc. on Tuesday recalled batches of zoledronic acid injections, a drug used to treat bone diseases such as osteoporosis or Paget’s disease, due to the possible presence of certain materials, particularly those that can cause blood clots.
The recall affects all lots of Zoledronic Acid Injection (Taro) 5mg/100ml (DIN 02415100) with references JKX1910A, JKX4318A, JKX5541A, HAC2371A, HAC4421A and HAD0156A.
Injecting certain materials may create a risk of injury such as These include inflammation or irritation of the veins, infection at the injection site or in other parts of the body, an allergic reaction, and the formation of blood clots that can travel to other parts of the body. In the most severe cases, blood clots can travel to the lungs and cause permanent or fatal lung damage.
Health Canada encourages people using this product to review their lots and return if affected by the recall.
If you have used the recalled product and have any health concerns, contact your doctor.